Markers of Altered Metabolism in Osteoarthritis

Journal of Rheumatology

Volumn 31, Issue SUPPL. 70, 2004, Pages 28-35

  Lohmander, L Stefan ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Department of Orthopaedic Surgery ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER;

BONE MATRIX; BONE METABOLISM; BONE RADIOGRAPHY; CONFERENCE PAPER; DISEASE SEVERITY; HIGH RISK PATIENT; MONITORING; OSTEOARTHRITIS; OUTCOMES RESEARCH; PATIENT CARE; PRIORITY JOURNAL; SURVIVAL;

EID: 84862351128     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials 2001;22:485-502.
2. Lohmander LS. Markers of cartilage metabolism in arthrosis. A review. Acta Orthop Scand 1991;62:623-32.
3. Simkin P, Bassett JE. Cartilage matrix molecules in serum and synovial fluid. Curr Opin Rheumatol 1995;7:346-51.
4. Lohmander LS, Dahlberg L, Eyre D, Lark M, Thonar EJ, Ryd L. Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities. Osteoarthritis Cartilage 1998;6:351-61.
5. Lohmander LS, Atley LM, Pietka TA, Eyre DR. The release of cross-linked peptides from type II collagen into human joint fluid is increased early after joint insult and in osteoarthritis. Arthritis Rheum 2003;48:3130-9.
6. Christensson B, Ryd L, Dahlberg L, Lohmander LS. Candida albicans arthritis after multiple intra-articular injections in a non-immunocompromised patient. Acta Orthop Scand 1993;64:695-8.
7. Lohmander LS, Hoermer LA, Dahlberg L, Roos H, Björnsson S, Lark MW. Stromelysin, tissue inhibitor and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol 1993;20:1362-8.
8. Lark MW, Bayne EK, Flanagan J, et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997;100:93-106.
9. Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan metabolism after knee injury and in osteoarthritis. Arthritis Rheum 1999;42:534-4.
10. Atley LM, Shao P, Shaffer K, Eyre DR. Matrix metalloproteinase-mediated release of immunoreactive telopeptides from cartilage type II collagen [abstract]. Trans Orthop Res Soc 1998;23:850.
11. Lohmander LS, Roos H. Knee ligament injury, surgery and osteoarthrosis - Truth or consequences? Acta Orthop Scand 1994;65:605-9.